Aarhus University Seal / Aarhus Universitets segl

Esben Skipper Sørensen

Evidence for Restricted Reactivity of ADAMDEC1 with Protein Substrates and Endogenous Inhibitors

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Jacob Lund, Department of Chemistry and Bioscience, Aalborg University, Denmark
  • Linda Troeberg, University of Oxford, Oxford, United Kingdom
  • Henrik Kjeldal, Department of Chemistry and Bioscience, Aalborg University, Denmark
  • Ole H Olsen, Novo Nordisk, Denmark
  • Hideaki Nagase, University of Oxford, Oxford, United Kingdom
  • Esben Skipper Sørensen
  • Henning R Stennicke, Novo Nordisk, Denmark
  • Helle H Petersen, Novo Nordisk, Denmark
  • Michael Toft Overgaard, Department of Chemistry and Bioscience, Aalborg University, Denmark

ADAMDEC1 is a proteolytically active metzincin metalloprotease displaying rare active site architecture with a zinc-binding Asp residue (Asp362). We previously demonstrated that substitution of Asp362 for a His residue, thereby reconstituting the canonical metzincin zinc-binding environment with three His zinc-ligands, increases the proteolytic activity. The protease also has an atypically short domain structure with an odd number of Cys residues in the metalloprotease domain. Here, we investigated how these rare structural features in the ADAMDEC1 metalloprotease domain impact the proteolytic activity, substrate specificity, and the effect of inhibitors. We identified carboxymethylated transferrin (Cm-Tf) as a new ADAMDEC1 substrate and determined the primary and secondary cleavage sites, which suggests a strong preference for Leu in the P1' position. Cys392 present in human, but only partially conserved within sequenced ADAMDEC1 orthologs, was found to be unpaired, and substitution of Cys392 for a Ser increased the reactivity with α2-macroglobulin, but not with casein or Cm-Tf. Substitution of Asp362 for His resulted in a general increase in proteolytic activity and a change in substrate specificity was observed with Cm-Tf. ADAMDEC1 was inhibited by the small molecule inhibitor Batimastat, but not by tissue inhibitor of metalloproteases (TIMP)-1, TIMP-2 or the N-terminal inhibitory domain of TIMP-3 (N-TIMP-3). However, N-TIMP-3 displayed profound inhibitory activity against the Asp362His variants with a reconstituted consensus metzincin zinc-binding environment. We hypothesize that these unique features of ADAMDEC1 may have evolved to escape from inhibition by endogenous metalloprotease inhibitors.

Original languageEnglish
JournalJournal of Biological Chemistry
Pages (from-to)6620-6629
Publication statusPublished - 6 Mar 2015

See relations at Aarhus University Citationformats

ID: 84902185